Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Public ClinicalTrials.gov record NCT05551273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Study identification
- NCT ID
- NCT05551273
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 29 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Selgantolimod Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2023
- Primary completion
- Oct 28, 2025
- Completion
- Apr 7, 2026
- Last update posted
- Apr 20, 2026
2023 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS | Birmingham | Alabama | 35222 | — |
| UCSD Antiviral Research Center CRS | San Diego | California | 92103 | — |
| The Ponce de Leon Center CRS | Atlanta | Georgia | 30308 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Weill Cornell Chelsea CRS | New York | New York | 10011 | — |
| Columbia P&S CRS | New York | New York | 10032-3732 | — |
| Weill Cornell Uptown CRS | New York | New York | 10065 | — |
| Chapel Hill CRS | Chapel Hill | North Carolina | 27599 | — |
| Greensboro CRS Site# 3203 | Greensboro | North Carolina | 27401 | — |
| Cincinnati Children's Hosp / Univ Hosp | Cincinnati | Ohio | 452292899 | — |
| Case CRS Site ID# 2501 | Cleveland | Ohio | 44106 | — |
| Ohio State University CRS | Columbus | Ohio | 43210 | — |
| Univ of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) CRS | Nashville | Tennessee | 37204 | — |
| Houston AIDS Research Team CRS | Houston | Texas | 77030 | — |
| University of Washington AIDS CRS | Seattle | Washington | 98104-9929 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05551273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05551273 live on ClinicalTrials.gov.